tri-1

TRi-1 是不可逆的胞质硫氧还蛋白还原酶1 的特异性抑制剂(IC50:12 nM)。它有抗肿瘤作用，且线粒体毒性很小。

1,2,3-Tri-10(Z)-undecenoyl glycerol 是一种三酰甘油，其在 sn-1、sn-2 和 sn-3 位置均连接有 10-Undecenoic acid。

1,2,3-Tri-13(E)-docosenoyl glycerol, a triacylglycerol featuring 13(E)-docosenoic acid at the \(sn-1\), \(sn-2\), and \(sn-3\) positions, transiently elevates heart triglyceride levels in weanling rats when administered as 15% of a calcium-deficient diet, with levels returning to baseline after 28 days.

1,2,3-Tri-11(Z)-eicosenoyl glycerol, a triacylglycerol with 11(Z)-eicosenoic acid at the sn-1,sn-2, and sn-3 positions, serves as an internal standard for quantifying triacylglycerols in seed and olive oils.

Tri-10(Z)-pentadecenoin (1,2,3-Tri-10(Z)-pentadecenoyl glycerol) 是一种三酰甘油，其在 sn-1、sn-2 和 sn-3 上均含有10(Z)-戊烯酸。

Tri-11(E)-eicosenoin 是一种用于药物递送的脂质，常用于制备脂质纳米颗粒 (LNP)。

Tri-11(Z),14(Z),17(Z)-eicosatrienoin 是一种脂质，能够用于制备脂质纳米颗粒 (LNP) 以应用于药物递送系统。

Tri-11(Z)-octadecenoin 是一种用于药物递送的脂质，可以用于制备脂质纳米颗粒 (LNP)。

Tri-10(Z)-nonadecenoin 是一种用于药物递送的脂质，可用于制备脂质纳米颗粒 (LNP)。

Tri-11(Z),14(Z)-eicosadienoin 是一种脂质，适用于制备用于药物递送的脂质纳米颗粒 (LNP)。

RMC-6291 是一种可口服且具有高效性的 KRASG12C(ON) 抑制剂，具有抗癌抗肿瘤活性，通过空间阻断 RAS 效应子结合来发挥作用。RMC-6291 阻断 ERK 信号传导，促使 KRASG12C 突变 H358 细胞凋亡。

b-Casomorphin (1-3) Acetate 是一种具有阿片样物质作用的三肽。

Amino-Tri-(carboxyethoxymethyl)-methane, an ADC linker and PROTAC linker, is a cleavable PEG compound utilized for the synthesis of antibody-drug conjugates (ADCs)[1] and PEG-based PROTACs[2].

Azido-PEG4-amido-tri-(carboxyethoxymethyl)-methane is a PEG-based linker compound employed for the synthesis of PROTACs[1].

Azido-PEG4-Amido-tri-(t-butoxycarbonylethoxymethyl)-methane, a PEG-derived PROTAC linker, is employed for PROTAC synthesis[1].

Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-spec

Tri(Amino-PEG5-amide)-amine is a polyethylene glycol (PEG) derivative serving as a PEG-based proteolysis targeting chimera (PROTAC) linker, facilitating the synthesis of PROTACs[1].

Tri(t-butoxycarbonylethoxymethyl) ethanol, an alkyl/ether-based PROTAC linker, is suitable for synthesizing PROTACs[1].

Tris[[2-(tert-butoxycarbonyl)ethoxy]methyl]methylamine, a cleavable PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs). It is also a PEG-based PROTAC linker, specifically Amino-Tri-(t-butoxycarbonylethoxymethyl)-methane, widely used in the synthesis of PROTACs[1].

Amino-Tri-(m-PEG4-ethoxymethyl)-methane, a PEG-based PROTAC linker, serves as a valuable component for synthesizing PROTACs[1].

m-C-tri(CH2-PEG1-NHS ester) is a non-cleavable one-unit polyethylene glycol (PEG) linker employed for the synthesis of antibody-drug conjugates (ADCs)[1].

Tri(Amino-PEG3-amide)-amine is a polyethylene glycol (PEG)-derived linker employed for the synthesis of proteolysis-targeting chimeric molecules (PROTACs)[1].

Tri(Amino-PEG4-amide)-amine is a polyethylene glycol (PEG)-based linker compound utilized for the synthesis of proteolysis-targeting chimeras (PROTACs)[1].

Tri(Mal-PEG2-amide)-amine is a polyethylene glycol (PEG)-derived linker commonly employed for synthesizing proteolysis-targeting chimeras (PROTACs)[1].